73 results on '"Alfonso, John"'
Search Results
2. Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis
- Author
-
Feliciano-Alfonso, John E., Muñoz-Ortiz, Juliana, Marín-Noriega, María Alejandra, Vargas-Villanueva, Andrés, Triviño-Blanco, Laura, Carvajal-Saiz, Natalia, and de-la-Torre, Alejandra
- Published
- 2021
- Full Text
- View/download PDF
3. Inappropriate antibiotic prescribing for acute bronchiolitis in Colombia: a predictive model
- Author
-
Buendía, Jefferson Antonio and Feliciano-Alfonso, John Edwin
- Published
- 2021
- Full Text
- View/download PDF
4. Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis.
- Author
-
Vieira-Serna, Santiago, Peralta, Jonathan, Viveros-Carreño, David, Rodriguez, Juliana, Feliciano-Alfonso, John Edwin, and Pareja, Rene
- Published
- 2024
- Full Text
- View/download PDF
5. Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta-analysis: study protocol
- Author
-
Feliciano-Alfonso, John E., Vargas-Villanueva, Andrés, Marín, María Alejandra, Triviño, Laura, Carvajal, Natalia, Moreno, Manuela, Luna, Tatiana, Lopez de Mesa, Clara, Muñoz-Ortiz, Juliana, and de-la-Torre, Alejandra
- Published
- 2019
- Full Text
- View/download PDF
6. Possible Effects of the Changes in the Exercise of the Statutory Auditor
- Author
-
Herrera-Nova, Silvia Juliana, Gómez-Alfonso, John Alexander, Rueda-Serrano, Oscar, Almeida-Parra, Gloria, Peña-Duarte, Mario Andrés, and Pérez-Pérez, Sindy Mayerly
- Subjects
Cambios Normativos ,Statutory Auditor ,Revisor Fiscal ,Regulación ,Contador Público ,Professional Practice ,Public Accountant ,Regulatory ,Ejercicio Profesional ,Regulation - Abstract
Digital, El siguiente proyecto de investigación implica un estudio de tipo cualitativo; utilizando la recolección de documentos, cuyo enfoque va al ejercicio de la revisoría fiscal con el objetivo de analizar la normatividad actual que lo rige y los cambios que proponen el Consejo Técnico de Contaduría Pública (CTCP), sobre el alcance, ejercicio profesional, cumplimiento de las normas legales, ética profesional y futuro de la Revisoría Fiscal que tendrá en el país ya se de forma positiva o negativa por lo que esto será identificado mediante una matriz. Expuesto lo anterior hoy en día la imagen del revisor fiscal, se ha descubierto en diversos escándalos financieros derivados de desfalcos financieros, estafas empresariales y actos de corrupción, demostrando así que la revisoría fiscal trae diversos riesgos: ético, legales, financieros, operacionales, información financiera fraudulenta, evasión fiscal, entre otros; para así mediante la propuesta del CTCP permita que el Revisor Fiscal consolide su rol en la organización para salvaguardar los activos y mitigar las amenazas que se puedan presentar en las organizaciones, esto dada la importancia de su ejercicio como ente fiscalizador del estado colombiano, dado que brinda seguridad en que se estén cumpliendo con toda la normatividad que los regula. Al final del proceso de investigación, se logró identificar los diferentes cambios que plantea el CTCP para reglamentar de una mejor manera al revisor fiscal, con el propósito de mitigar los riesgos que conlleva a su ejercicio profesional. Adicionalmente, se evidenció que se necesita un estatuto de control a la práctica profesional, esto con la finalidad de integrar todas las normatividades existentes en un solo documento, y así no generar confusión referente a las normas que regulan al revisor fiscal., The following research project involves a qualitative study; using the collection of documents, whose focus goes to the exercise of the fiscal audit with the objective of analyzing the current regulations that govern it and the changes proposed by the Technical Council of Public Accounting (CTCP), on the scope, professional practice, compliance with the legal norms, professional ethics and future of the Statutory Auditor that it will have in the country in a positive or negative way, so this will be identified by means of a matrix. Given the above, today the image of the fiscal auditor has been discovered in various financial scandals derived from financial embezzlement, business fraud and acts of corruption, thus demonstrating that the fiscal audit brings various risks: ethical, legal, financial, operational, information fraudulent finance, tax evasion, among others; For this, through the proposal of the technical council of public accounting, it allows the Fiscal Auditor to consolidate his role in the organization to safeguard the assets and mitigate the threats that may arise in the organizations, this given the importance of his exercise as a supervisory entity of the Colombian state, since it provides security that they are complying with all the regulations that regulate them. At the end of the investigation process, it was possible to identify the different changes proposed by the CTCP to better regulate the fiscal auditor, with the purpose of mitigating the risks that his professional practice entails. Additionally, it was evidenced that a control statute is needed for professional practice, this in order to integrate all existing regulations in a single document, and thus not generate confusion regarding the regulations that regulate the fiscal auditor., Pregrado, Contador Público, Introducción .................................................................................................................................. 17 Planteamiento Problema ............................................................................................................... 19 Pregunta Problema ........................................................................................................................ 20 Justificación .................................................................................................................................. 21 Objetivo......................................................................................................................................... 23 Objetivo General ........................................................................................................................... 23 Objetivos Específicos.................................................................................................................... 23 Marco Conceptual ......................................................................................................................... 24 Marco Teórico............................................................................................................................... 28 Estado del Arte.............................................................................................................................. 52 Caracterización de la Situación Actual de la Revisoría Fiscal...................................................... 55 Ejercicio de la Revisoría Fiscal..................................................................................................... 55 Son Funciones del Revisor Fiscal ................................................................................................. 55 No Podrán ser Revisores Fiscales ................................................................................................. 58 Informe al Finalizar el Encargo .................................................................................................... 60 Memorandos de Recomendaciones............................................................................................... 60 Sanciones del Revisor Fiscal ........................................................................................................ 63 Sanciones Administrativas ............................................................................................................ 63 Sanciones de Tipo Penal ............................................................................................................... 63 Sanciones Civiles .......................................................................................................................... 63 Sanciones Disciplinarias .............................................................................................................. 64 Sanciones por Incumplimiento en Obligaciones Fiscales ............................................................ 64 Implicaciones en Materia Tributaria ............................................................................................. 64 La Importancia de la Firma de un Revisor Fiscal en las Declaraciones Fiscales....................... 65 ¿Qué Deben Tener en Cuenta los Revisores Fiscales en la Revisión Tributaria? ....................... 66 Objetivo de la Revisoría Fiscal ..................................................................................................... 66 ¿Qué Debilidades Tiene la Revisoría Fiscal? ............................................................................... 67 ¿Qué Amenazas Tiene la Revisoría Fiscal? .................................................................................. 68 ¿Qué Oportunidades Tiene la Revisoría Fiscal? ........................................................................... 68 ¿Qué Fortalezas Tiene la Revisoría Fiscal? .................................................................................. 69 ¿Cuáles son los Derechos del Revisor Fiscal? .............................................................................. 69 ¿Cuáles son los Deberes del Revisor Fiscal? ................................................................................ 71 ¿Quiénes son los Obligados a Nombrar Revisor Fiscal? .............................................................. 72 ¿Cuáles son las Cualidades Para ser Revisor Fiscal?.................................................................... 73 ¿Cuáles son los Conflictos de Interés de un Revisor Fiscal? ........................................................ 73 ¿Cuáles son las Inhabilidades Para el Ejercicio del Cargo de Revisor Fiscal?............................. 74 ¿Cuáles son las Prohibiciones en el Ejercicio del Cargo de Revisor Fiscal?................................ 74 ¿Cómo es la Elección y Periodo del Revisor Fiscal?.................................................................... 74 Determinar las Diferencias y Puntos de Encuentro Entre las Diferentes Propuestas a la Revisoría Fiscal en Colombia, a 2022, Mediante el Uso de una Matriz ....................................................... 75 Metodología .................................................................................................................................. 81 Tipo de Estudio ............................................................................................................................. 81 Tratamiento y Análisis de la Información..................................................................................... 81 Fuentes de Información................................................................................................................. 81 Conclusiones ................................................................................................................................. 82 Recomendaciones.......................................................................................................................... 84 Referencias Bibliográficas ............................................................................................................ 85
- Published
- 2022
7. Making Sense of Composite Endpoints in Clinical Research.
- Author
-
Baracaldo-Santamaría, Daniela, Feliciano-Alfonso, John Edwin, Ramirez-Grueso, Raul, Rojas-Rodríguez, Luis Carlos, Dominguez-Dominguez, Camilo Alberto, and Calderon-Ospina, Carlos Alberto
- Subjects
- *
MEDICAL research , *GOVERNMENT agencies , *DRUG approval - Abstract
Multiple drugs currently used in clinical practice have been approved by regulatory agencies based on studies that utilize composite endpoints. Composite endpoints are appealing because they reduce sample size requirements, follow-up periods, and costs. However, interpreting composite endpoints can be challenging, and their misuse is not uncommon. Incorrect interpretation of composite outcomes can lead to misleading conclusions that impact patient care. To correctly interpret composite outcomes, several important questions should be considered. Are the individual components of the composite outcome equally important to patients? Did the more and less important endpoints occur with similar frequency? Do the component endpoints exhibit similar relative risk reductions? If these questions receive affirmative answers, the use and interpretation of the composite endpoint would be appropriate. However, if any component of the composite endpoint fails to satisfy the aforementioned criteria, interpretation can become difficult, necessitating additional steps. Regulatory agencies acknowledge these challenges and have specific considerations when approving drugs based on studies employing composite endpoints. In conclusion, composite endpoints are valuable tools for evaluating the efficacy and net clinical benefit of interventions; however, cautious interpretation is advised. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. sj-docx-1-taw-10.1177_20420986221127501 – Supplemental material for Definition of self-medication: a scoping review
- Author
-
Baracaldo-Santamaría, Daniela, Trujillo-Moreno, Maria José, Pérez-Acosta, Andrés M., Feliciano-Alfonso, John Edwin, Calderon-Ospina, Carlos-Alberto, and Soler, Franklin
- Subjects
FOS: Clinical medicine ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-docx-1-taw-10.1177_20420986221127501 for Definition of self-medication: a scoping review by Daniela Baracaldo-Santamaría, Maria José Trujillo-Moreno, Andrés M. Pérez-Acosta, John Edwin Feliciano-Alfonso, Carlos-Alberto Calderon-Ospina and Franklin Soler in Therapeutic Advances in Drug Safety
- Published
- 2022
- Full Text
- View/download PDF
9. Systematic review and cost‐utility of high flow nasal cannula versus continuous positive airway pressure in children with acute severe or moderate bronchiolitis in Colombia.
- Author
-
Buendía, Jefferson A., Feliciano‐Alfonso, John E., and Florez, Ivan D.
- Published
- 2022
- Full Text
- View/download PDF
10. Cost-utility of azithromycin in patients with severe asthma.
- Author
-
Buendía, Jefferson Antonio, Patiño, Diana Guerrero, and Feliciano-Alfonso, John Edwin
- Subjects
AZITHROMYCIN ,ASTHMATICS ,MARKOV processes ,COST estimates ,SENSITIVITY analysis ,COUGH - Abstract
An important proportion of asthma patients remain uncontrolled despite the use of inhaled corticosteroids and long-acting beta-agonists. Some add-on therapies, like azithromycin, have been recommended for this subgroup of patients. The purpose of this study was to assess the cost-effectiveness of azithromycin as an add-on therapy to ICS + LABA for patients with severe asthma. A probabilistic Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with severe asthma in Colombia. The total costs and QALYS of two interventions, including standard therapy (ICS + LABA), and add-on therapy with azithromycin, were calculated over a lifetime horizon. Multiple sensitivity analyses were conducted. Cost-effectiveness was evaluated at a willingness-to-pay value of $19,000. The model suggests a potential gain of 0.037 QALYs per patient per year on azithromycin, with a difference of US $718 in favor of azithromycin, showing dominance with respect to SOC. A position of dominance negates the need to calculate an incremental cost-effectiveness ratio. In the deterministic sensitivity analyses, our base‐case results were robust to variations in all assumptions and parameters. Add-on therapy with azithromycin was found to be cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Additional file 2 of Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis
- Author
-
Feliciano-Alfonso, John E., Muñoz-Ortiz, Juliana, Marín-Noriega, María Alejandra, Vargas-Villanueva, Andrés, Triviño-Blanco, Laura, Carvajal-Saiz, Natalia, and de-la-Torre, Alejandra
- Subjects
Data_FILES - Abstract
Additional file 2.
- Published
- 2021
- Full Text
- View/download PDF
12. Additional file 3 of Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis
- Author
-
Feliciano-Alfonso, John E., Muñoz-Ortiz, Juliana, Marín-Noriega, María Alejandra, Vargas-Villanueva, Andrés, Triviño-Blanco, Laura, Carvajal-Saiz, Natalia, and de-la-Torre, Alejandra
- Subjects
Data_FILES - Abstract
Additional file 3.
- Published
- 2021
- Full Text
- View/download PDF
13. Additional file 1 of Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis
- Author
-
Feliciano-Alfonso, John E., Muñoz-Ortiz, Juliana, Marín-Noriega, María Alejandra, Vargas-Villanueva, Andrés, Triviño-Blanco, Laura, Carvajal-Saiz, Natalia, and de-la-Torre, Alejandra
- Subjects
Data_FILES - Abstract
Additional file 1.
- Published
- 2021
- Full Text
- View/download PDF
14. Additional file 4 of Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis
- Author
-
Feliciano-Alfonso, John E., Muñoz-Ortiz, Juliana, Marín-Noriega, María Alejandra, Vargas-Villanueva, Andrés, Triviño-Blanco, Laura, Carvajal-Saiz, Natalia, and de-la-Torre, Alejandra
- Subjects
Data_FILES - Abstract
Additional file 4.
- Published
- 2021
- Full Text
- View/download PDF
15. Estudio para el posicionamiento e imagen de la marca proteja
- Author
-
Simanca H., Fredys A., Alfonso, John, Neuto, Daniel, blanco garrido, fabian, Hernandez, Miguel, and Arias, Jaime
- Subjects
Fibrocemento ,Atributos ,Percepción ,Posicionamiento de marca - Abstract
Este artículo es el resultado de un proyecto de investigación llevado a cabo en la ciudad de Bogotá D.C. como parte de la gestión y análisis estratégico de la empresa Etex Colombia, para posicionar su marca Proteja en el mercado colombiano. El objetivo principal de la investigación fue identificar los principales atributos y percepciones que actualmente tienen las empresas constructoras que usan techos en fibrocemento en proyectos de vivienda de interés social (VIS). El estudio es no experimental de tipo cuantitativo mediante la aplicación de encuestas y análisis sobre la población representada por las empresas constructoras que caracterizan la imagen y el posicionamiento de la marca Proteja, gracias a la elaboración de mapas perceptivos que permiten un análisis detallado de cómo se posicionan. Los resultados demuestran las principales características de las tres marcas afectadas en el mercado de los techos de fibrocemento analizados, que sirven de base para reconocer y diferenciar las ventajas y desventajas competitivas comerciales, de calidad y de servicio para cada una de estas marcas; estos hallazgos permitirán definir los factores que son diferenciadores en la marca Proteja y los definitivos para lograr una mejor posición en el mercado, además liderar el segmento y llegar a la mente del consumidor, teniendo en cuenta que una marca puede sobrevivir a sus productos, a sus dueños e incluso al inexorable paso del tiempo
- Published
- 2020
16. Definition of self-medication: a scoping review.
- Author
-
Baracaldo-Santamaría, Daniela, Trujillo-Moreno, Maria José, Pérez-Acosta, Andrés M., Feliciano-Alfonso, John Edwin, Calderon-Ospina, Carlos-Alberto, and Soler, Franklin
- Published
- 2022
- Full Text
- View/download PDF
17. Additional file 1: of Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta-analysis: study protocol
- Author
-
Feliciano-Alfonso, John, Vargas-Villanueva, Andrés, Marín, María, Triviño, Laura, Carvajal, Natalia, Moreno, Manuela, Luna, Tatiana, Mesa, Clara Lopez De, Muñoz-Ortiz, Juliana, and De-La-Torre, Alejandra
- Abstract
Electronic search strategies. (DOCX 19 kb)
- Published
- 2019
- Full Text
- View/download PDF
18. CHAPTER 143 - Plexopathy—Brachial
- Author
-
Ensrud, Erik, King, John C., and Alfonso, John D.
- Published
- 2015
- Full Text
- View/download PDF
19. CHAPTER 144 - Plexopathy—Lumbosacral
- Author
-
Hacker, Hope S., King, John C., and Alfonso, John D.
- Published
- 2015
- Full Text
- View/download PDF
20. Implementación de un sistema de gestión de la calidad basado en la norma NTC- ISO 9001: 2015 en la empresa Avícola el Manantial
- Author
-
Huertas Forero, Germán Antonio, Ramírez Alfonso, John Fredy, Huertas Forero, Germán Antonio, and Ramírez Alfonso, John Fredy
- Abstract
La implementación del sistema de gestión de la calidad basado en la norma NTC-ISO 9001: 2015 en la empresa Avícola el Manantial ubicada en la ciudad de Duitama, Boyacá. La primera etapa del proyecto fue el diagnóstico inicial en el cual se evaluó la situación de la organización frente a los requerimientos de la norma, se estructuró por medio de un análisis PESTAL los factores inherentes e influyentes. A partir de los resultados se estructuró el plan de implementación en el cual se delegaron las responsabilidades pertinentes para el sistema.
- Published
- 2016
21. Papel de la Rosuvastatina en el paciente con alto riesgo cardiovascular
- Author
-
Feliciano-Alfonso, John E
- Subjects
Inhibidores de Hidroximetilglutaril-CoA Reductasas ,enfermedades ardiovasculares ,dislipidemias ,nutritional and metabolic diseases ,Cost-Effectiveness Evaluation ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,dyslipidemias ,evaluación de Costo-Efectividad ,cardiovascular diseases - Abstract
Statins are the lipid-lowering drug family of first choice in situations of hypercholesterolemia or mixed dyslipidemia with predominant increase in cholesterol. The evidence shows conclusively that each one of the commercially available statins have proven benefits on outcomes of cardiovascular morbidity and mortality. However, rosuvastatin has certain pharmacokinetic efficacy and cost-effectiveness characteristics that make it an attractive molecule to be the statin of choice in patients at high cardiovascular risk. Las estatinas son la familia farmacológica hipolipemiante de primera opción en situaciones de hipercolesterolemia o dislipiemia mixta con predominio de aumento en el colesterol. La evidencia demuestra contundentemente que cada una de las estatinas disponibles en el mercado ha mostrado beneficios en desenlaces de morbi-mortalidad cardiovascular. Sin embargo, la rosuvastatina presenta ciertas características farmacocinéticas de eficacia y de costo-efectividad que la hacen una molécula atractiva para ser la estatina de elección en pacientes de alto riesgo cardiovascular.
- Published
- 2013
22. Cardiovascular risk factors and metabolic syndrome in a population of young students from the National University of Colombia
- Author
-
Feliciano-Alfonso, John Edwin, Mendivil, Carlos Olimpo, Ariza, Iván Darío Sierra, and Pérez, Clara Eugenia
- Subjects
Risk factors ,Adolescent ,Metabolic syndrome X obesity ,Fatores de risco ,Obesidade ,Síndrome X metabólica ,Alcohol consumption ,Consumo de bebidas alcoólicas ,Adolescente - Abstract
OBJECTIVE: To estimate prevalence and distribution of cardiovascular risk factors and Metabolic Syndrome (MS) in young individuals admitted to the National University of Colombia in Bogotá. METHODS: An analytic cross-sectional study was conducted in a sample of 249 individuals of both genders aged 15 to 20 years. A questionnaire was personally administered to collect demographic, socioeconomic, smoking, perinatal, and women's health data. Anthropometric measurements, blood pressure, and a fasting blood sample were taken. Prevalence of MS was determined and compared using criteria from several qualified institutions. RESULTS: We found a high prevalence of smoking (18.9%), arterial prehypertension (14.1%) and overweight (11.2%), 9.2% of study participants had prediabetes, and the most frequent dyslipidemia was low HDL cholesterol (13.3%). Alcoholic beverage consumption was declared by 60.6% of study terol and plasma triglyceride levels. Gestational age at birth was inversely associated with presence of low HDL cholesterol levels and high blood pressure. Prevalence of the MS varied markedly according to the definition employed: 9.2% using REGODCI (Research Group on Diabetes and Chronic Illnesses) criteria, 2% using IDF (International Diabetes Federation) criteria, and 2.4% using AHA (American Heart Association) criteria. CONCLUSION: The encountered prevalence of modifiable cardiovascular risk factors justifies promotion of therapeutic lifestyle changes among this age group in Colombia. Further harmonization of MS criteria in young individuals is needed. OBJETIVO: Estimar a prevalência e distribuição de fatores de risco cardiovasculares e da síndrome X metabólica (SM) em indivíduos jovens admitidos na Universidade Nacional da Colômbia, em Bogotá. MÉTODOS: Foi realizado um estudo analítico transversal em uma amostra de 249 indivíduos de ambos os sexos, com idades entre 15 e 20 anos. Um questionário foi administrado pessoalmente para recolher dados demográficos e socioeconômicos, presença ou ausência de tabagismo, características perinatais e sobre saúde da mulher. Medidas antropométricas e de pressão arterial foram realizadas, e uma amostra de sangue em jejum foi coletada. A prevalência da SM foi determinada e comparada utilizando-se os critérios de diferentes instituções especializadas. RESULTADOS: Encontramos uma alta prevalência de tabagismo (18,9%), pré-hipertensão arterial (14,1%) e sobrepeso (11,2%); 9,2% dos participantes tinham pré-diabetes, e a mais frequente dislipidemia foi baixo HDL-colesterol (13,3%). Um total de 66,6% dos participantes declarou consumir bebidas alcoólicas. O índice de massa corporal foi positivamente associado a aumento na pressão arterial, colesterol LDL e triglicérides plasmáticos. A idade gestacional ao nascimento foi inversamente associada a baixo HDL colesterol e à pressão arterial elevada. A prevalência de SM variou acentuadamente, de acordo com a definição empregada: 9,2% segundo REGODCI (Grupo de Pesquisa em Diabetes e Doenças Crônicas), 2% segundo IDF (International Diabetes Federation), e 2,4% segundo AHA (American Heart Association). CONClUSÃO: A prevalência encontrada de fatores de risco cardiovasculares justifica o incentivo a mudanças de estilo de vida neste grupo etário na Colômbia. Uma maior padronização dos critérios definidores de SM em indivíduos jovens é necessária.
- Published
- 2010
23. Elevando el colesterol HDL: ¿Cuál es la mejor estrategia?
- Author
-
Alfonso, John Edwin Feliciano and Ariza, Iván Darío Sierra
- Subjects
Tabagismo ,Fibratos ,Smoking ,Statins ,lipids (amino acids, peptides, and proteins) ,Colesterol HDL ,Rimonabant ,Fibrates ,Estatinas ,Cholesterol HDL - Abstract
Após atingir as metas para os níveis de LDL-colesterol, é imperativo alcançar a meta do HDL-colesterol, por suas conhecidas propriedades antiaterogênicas confirmadas amplamente em muitos estudos epidemiológicos. Esta revisão analisa de maneira objetiva e concisa as diversas alternativas disponíveis na prática clínica diária para aumentar os níveis de HDL-colesterol em nosoos pacientes, com o objetivo de alcançar melhores prognósticos em termos de morbimortalidade cardiovascular. After having reached the objective for the LDL cholesterol levels, it becomes imperative to reach the objective for HDL cholesterol, known for its anti-atherogenic properties, generally confirmed in many epidemiological studies. This review deals, in a clear and concise manner, with the different alternatives available in daily clinical practice to raise the HDL cholesterol levels of patients, to achieve better outcomes in terms of morbidity and mortality in cardiovascular disease.
- Published
- 2008
24. Sistema endocanabinoide: modificando los factores de riesgo cardiovascular
- Author
-
Feliciano Alfonso, John Edwin, Mendivil Anaya, Carlos Olimpo, and Sierra Ariza, Iván Dario
- Subjects
lcsh:R5-920 ,receptores canabinoides ,tabaquismo ,lcsh:R ,endocanabinoides ,lcsh:Medicine ,factores de riesgo ,leptina ,lcsh:Medicine (General) ,obesidad ,rimonabant - Abstract
La necesidad de alcanzar un tratamiento óptimo para el tabaquismo, la obesidad y sus comorbilidades, conocidos factores de riesgo cardiovascular, ha fomentado la búsqueda de objetivos terapéuticos novedosos. Es el caso del sistema endocanabinoide, involucrado en diversos fenómenos fisiológicos entre los que se encuentran el refuerzo de ciertos comportamientos y la regulación del apetito. La sobreactivación de este sistema altera la homeostasis corporal predisponiendo a dependencias o a un aumento en la ingesta alimentaria, lo que puede traducirse en tabaquismo u obesidad. La intervención farmacológica sobre el sistema endocanabinoide puede contribuir al manejo de estos factores de riesgo cardiovascular, teniendo en cuenta que a tales beneficios se suman otros independientes de la suspensión del tabaquismo o la reducción de peso, como el aumento del colesterol de alta densidad, la disminución de triglicéridos y la mejoría del control glucémico en pacientes con diabetes. Ensayos clínicos controlados aleatorizados adelantados en poblaciones con diferentes características, han evaluado la utilidad de la regulación farmacológica del sistema endocanabinoide; confirmando su eficacia en personas con factores de riesgo cardiovascular establecidos.
- Published
- 2006
25. Panel nacional de expertos sobre la atención de la gastroparesia diabética.
- Author
-
Yepes-Cortés, Carlos Augusto, Yurgaky-Sarmiento, James Milthón, Feliciano-Alfonso, John E., Linares, Diana Paola, Arenas-Quintero, Henry Mauricio, Rey, Adriana Margarita, Guzmán-Gómez, Guillermo Édinson, Stephens-Leal, Ingrid, Ramírez-Rincón, Alex, Ríos, Germán, and Wandurraga-Sánchez, Edwin Antonio
- Abstract
Copyright of Revista de la ALAD is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
26. Rosuvastatin: role in cardioascular high-risk patient
- Author
-
Feliciano-Alfonso, John E. and Feliciano-Alfonso, John E.
- Abstract
Statins are the lipid-lowering drug family of first choice in situations of hypercholesterolemia or mixed dyslipidemia with predominant increase in cholesterol. The evidence shows conclusively that each one of the commercially available statins have proven benefits on outcomes of cardiovascular morbidity and mortality. However, rosuvastatin has certain pharmacokinetic efficacy and cost-effectiveness characteristics that make it an attractive molecule to be the statin of choice in patients at high cardiovascular risk., Las estatinas son la familia farmacológica hipolipemiante de primera opción en situaciones de hipercolesterolemia o dislipiemia mixta con predominio de aumento en el colesterol. La evidencia demuestra contundentemente que cada una de las estatinas disponibles en el mercado ha mostrado beneficios en desenlaces de morbi-mortalidad cardiovascular. Sin embargo, la rosuvastatina presenta ciertas características farmacocinéticas de eficacia y de costo-efectividad que la hacen una molécula atractiva para ser la estatina de elección en pacientes de alto riesgo cardiovascular.
- Published
- 2013
27. Comentarios a artículos de actualidad en diabetes.
- Author
-
Feliciano-Alfonso, John E.
- Published
- 2016
28. Endocannabinoid system: modifying cardiovascular risk factors
- Author
-
Feliciano Alfonso, John Edwin, Mendivil Anaya, Carlos Olimpo, Sierra Ariza, Iván Dario, Feliciano Alfonso, John Edwin, Mendivil Anaya, Carlos Olimpo, and Sierra Ariza, Iván Dario
- Abstract
The need for an optimal treatment for smoking, obesity and their comorbidities, well-known cardiovascular risk factors; has prompted the search for novel therapeutic targets. This is the case of the endocannabinoid system, involved in several physiological phenomena including the reinforcement of certain behaviors and the regulation of appetite.Overactivation of the endocannabinoid system alters body homeostasis, predisposing to addictions or to an increase in food intake; which may in turn result in the development of tobacco addiction and obesity. Pharmacological intervention on the endocannabinoid system may contribute to the management of these cardiovascular risk factors,bearing in mind that there are other, additional benefits like reduction of plasma levels of triglycerides, elevation of high-density-lipoprotein cholesterol and improvements in glycemic control in diabetic patients. Randomised controlled clinical trials performed in populations of different characteristics have evaluated the utility of pharmacological regulation of the endocannabinoid system; confirming its efficacy in people with established cardiovascular risk factors., La necesidad de alcanzar un tratamiento óptimo para el tabaquismo, la obesidad y sus comorbilidades, conocidos factores de riesgo cardiovascular, ha fomentado la búsqueda de objetivos terapéuticos novedosos. Es el caso del sistema endocanabinoide, involucrado en diversos fenómenos fisiológicos entre los que se encuentran el refuerzo de ciertos comportamientos y la regulación del apetito.La sobreactivación de este sistema altera la homeostasis corporal predisponiendo a dependencias o a un aumento en la ingesta alimentaria, lo que puede traducirse en tabaquismo u obesidad. La intervención farmacológica sobre el sistema endocanabinoide puede contribuir al manejo de estos factores de riesgo cardiovascular, teniendo en cuenta que a tales beneficios se suman otros independientes de la suspensión del tabaquismo o la reducción de peso, como el aumento del colesterol de alta densidad, la disminución de triglicéridos y la mejoría del control glucémico en pacientes con diabetes.Ensayos clínicos controlados aleatorizados adelantados en poblaciones con diferentes características, han evaluado la utilidad de la regulación farmacológica del sistema endocanabinoide; confirmando su eficacia en personas con factores de riesgo cardiovascular establecidos.
- Published
- 2006
29. Contributors
- Author
-
Able, Antoinne C., Sosa, Sol M. Abreu, Adib, Farshad, Agarwal, Meena, Aghalar, Maryam R., Akuthota, Venu, Alfonso, John D., Alleva, Joseph T., Altschuler, Eric L., Amadera, Joao E.D., Amy, Eduardo, Babushkina, Anna, Bach, John R., Bailey, Allison, Bang, Moon Suk, Bavishi, Alpeshkumar, Beckworth, William J., Bengtson, Keith A., Berman, Andrew R., Bhatti, Omar M., Bienkowski, Peter, Bockenek, William L., Bogie, Kath, Borg, Kristian, Borg-Stein, Joanne, Bosques, Glendaliz, Bowen, Jay E., Brault, Jeffrey S., Braverman, Colonel Steven E., Braza, Diane W., Burke, David T., Caban, Mabel, Cabrera, Alison L., Cabrera, Juan A., Campbell, Mark, Carter, Gregory T., Cassidy, Charles, Cassius, David A., Cheville, Andrea, Chew, Kelvin, Childers, Martin K., Chinratanalab, Sallaya, Chow, Chien, Chung, Victor, Clinchot, Daniel M., Colberg, Ricardo, Colbert, Melissa, Craig, Earl J., Cui, Di, Curtis, Christine, Custodio, Christian M., Davis, Alan M., Deimel, George W., IV, Del Toro, David R., Diesselhorst, Matthew M., Dillingham, Timothy R., Dreyer, Susan J., Dudek, Nancy, Dudkiewicz, Israel, Dugan, Sheila, Eapen, Blessen C., Earle, Jennifer L., Ebenbichler, Gerold R., Egyhazi, Rachel, El Abd, Omar, Eliason, Jeffrey B., Ellenberg, Maury, Ellenberg, Michael J., Ennis, Jesse D., Ensrud, Erik, M. Esser, Stephan, Fast, Avital, Feeney, Richard, Feldman, Jeffery B., Finnoff, Jonathan T., Foster, Leslie S., Foye, Patrick M., Fredericson, Michael, Frontera, Joel E., Frontera, Walter R., Gittler, Michelle, Glenn, Mel B., Gonzalez, Peter, González-Fernández, Marlís, Groomes, Thomas E., Grosser, Dawn M., Guo, H. Michael, Gupta, Navneet, Hacker, Hope S., Hall, Lori, Hanada, Ed, Hanson, Toni J., Harrington, Amanda L., Hartigan, David E., Herman, Seth D., Herrera, Joseph E., Ho, Chester H., Hoch, Anne Z., Holm, Jason, Hon, Alice J., Hudgins, Thomas H., Ibanez, Katarzyna, Ibrahim, Mahmud M., Imamura, Marta, Imamura, Satiko T., Isaac, Zacharia, Joseph, Rathi L., Joshi, Shivang, Joyce, Nanette C., Jung, Se Hee, Kay, Jonathan, Kaynan, Ayal M., Keel, John C., Kent, Robert, Keplinger, Florian S., Kigner, Stuart, Kile, Todd A., King, John C., Kirschbaum, Neil, Klausmeyer, Melissa A., Kortte, Jason H., Krabak, Brian J., Latlief, Gail, Lee, Sammy M., Lee, Shi-Uk, Lennard, Ted A., Lento, Paul, Lexell, Jan, Lim, Peter A.C., Lin, Cindy, Lindgren, Karl-August, Lirofonis, Vasilios A., Loder, Elizabeth, Lopez, Edrick, Malanga, Gerard A., Martin, Julie, Mascarinas, Rafael, Massengale, Jill, Matsuo, Koichiro, McCarthy, Marissa, McInnis, Kelly C., McIntosh, Peter M., Meleger, Alec L., Merritt, Bryan, Micheli, Lyle J., Micheo, William, Miller, Matthew E., Miranda, Gerardo, Mohr, Nathan, Montero, Daniel P., Mookerjee, S. Jit, Mostoufi, Ali, Mudgal, Chaitanya S., Najera, Larry V., III, Nesathurai, Shanker, Nordin, Jess, O’Neill, Carina J., Origenes, Andrea K., Ortiguera, Cedric J., Osborne, Michael D., Palmer, Jeffrey B., Pasquina, Paul F., Patel, Atul T., Paterno, Josemaria, Perkash, Inder, Phillips, Edward M., Pimentel, Daniel C., Pobre, Thomas E., Posthuma, Rebecca, Putnam, Alison R., Rainville, James, Ramachandran, V.S., Ring, David, Riutta, Justin, Rivera-Vega, Alexandra, Rizzo, Thomas D., JR., Rosenberg, Darren, Rutkove, Seward B., Sabharwal, Sunil, Santiago, Francisco H., Scardina, Robert J., Schaufele, Michael K., Schneider, Jeffrey C., Scott, Steven, Sein, Michael, Sepúlveda, Fernando, Sergent, John, Shah, Vivek M., Sharma, Nutan, Sheikh, Huma, Shubert, Sarah, Siddiqui, Imran J., Silver, Julie K., Silver, Kenneth H., Singla, Aneesh, Slesinski, Michael, Slovik, David M., Spindler, Kurt, Standley, Do, Joseph, Stein, Joel, Stilp, Sonja K., Stitik, Todd P., Stretanski, Michael F., Stubblefield, Michael D., Tate, Jordan L., Therattil, Maya, Thomas, Ann-Marie, Thomas, Mark A., Tran, Jiaxin, Trudel, Guy, Urbisci, Tony, Vadivelu, Sathya, Vallarino, Ramon, JR., Verduzco-Gutierrez, Monica, Vora, Ariana, Wallace, Adam, Weinman, Beth M., Weiss, Jay M., Weiss, Lyn D., Wexler, David, Wierbicky, Jane, Wieting, J. Michael, Wilkins, Allen N., Williams, Faren H., Yin, Amy X., Young, Mark, and Zhao, Meijuan
- Published
- 2015
- Full Text
- View/download PDF
30. Búsqueda, evaluación y síntesis de la evidencia de efectividad y seguridad en evaluaciones de tecnología : manual metodológico
- Author
-
Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana, Rojas Reyes, María Ximena, Gaitán Duarte, Hernando Guillermo, Feliciano Alfonso, John Edwin, Pontificia Universidad Javeriana. Facultad de Medicina. Instituto de Genética Humana, Rojas Reyes, María Ximena, Gaitán Duarte, Hernando Guillermo, and Feliciano Alfonso, John Edwin
- Abstract
Autor Gaitán Duarte, Hernando G.; Rojas Reyes, María Ximena; Feliciano-Alfonso, John Fecha Jun 2017 Descarga: Español (3252 descargas) DOI http://dx.doi.org/10.18235/0000748 EDITOR Gaitán Duarte, Hernando G.;Rojas Reyes, María Ximena El Banco Interamericano de Desarrollo (BID) ha venido desarrollando una serie de proyectos y actividades regionales en el sector salud encaminadas a fortalecer los procesos de priorización del gasto sanitario en los países de América Latina y el Caribe. En este marco, y con el objeto de brindar herramientas para una asignación eficiente de este gasto, el Banco seencuentra en el proceso de implementación de un proyecto para mejorar la gestión de medicamentos de alto impacto financiero. El proyecto busca que los tomadores de decisiones a nivel político dispongan de información válida, robusta, actual y oportuna para definir qué medicamentos financiar con recursos públicos y a qué precio.
31. Individuality and community : the social and political thought of John Dewey /
- Author
-
Damico, Alfonso John
- Subjects
- Political Science, Political participation, Education
- Published
- 1971
32. Cardiovascular risk factors and metabolic syndrome in a population of young students from the National University of Colombia.
- Author
-
Feliciano-Alfonso JE, Mendivil CO, Ariza ID, and Pérez CE
- Subjects
- Adolescent, Birth Weight, Cardiovascular Diseases diagnosis, Colombia epidemiology, Epidemiologic Methods, Female, Gestational Age, Humans, Male, Metabolic Syndrome diagnosis, Metabolic Syndrome etiology, Reference Values, Risk Factors, Students statistics & numerical data, Universities, Young Adult, Cardiovascular Diseases etiology, Metabolic Syndrome epidemiology
- Abstract
Objective: To estimate prevalence and distribution of cardiovascular risk factors and Metabolic Syndrome (MS) in young individuals admitted to the National University of Colombia in Bogotá., Methods: An analytic cross-sectional study was conducted in a sample of 249 individuals of both genders aged 15 to 20 years. A questionnaire was personally administered to collect demographic, socioeconomic, smoking, perinatal, and women's health data. Anthropometric measurements, blood pressure, and a fasting blood sample were taken. Prevalence of MS was determined and compared using criteria from several qualified institutions., Results: We found a high prevalence of smoking (18.9%), arterial prehypertension (14.1%) and overweight (11.2%), 9.2% of study participants had prediabetes, and the most frequent dyslipidemia was low HDL cholesterol (13.3%). Alcoholic beverage consumption was declared by 60.6% of study terol and plasma triglyceride levels. Gestational age at birth was inversely associated with presence of low HDL cholesterol levels and high blood pressure. Prevalence of the MS varied markedly according to the definition employed: 9.2% using REGODCI (Research Group on Diabetes and Chronic Illnesses) criteria, 2% using IDF (International Diabetes Federation) criteria, and 2.4% using AHA (American Heart Association) criteria., Conclusion: The encountered prevalence of modifiable cardiovascular risk factors justifies promotion of therapeutic lifestyle changes among this age group in Colombia. Further harmonization of MS criteria in young individuals is needed.
- Published
- 2010
- Full Text
- View/download PDF
33. [New therapies for diabetes: beyond injectable insulin and oral antidiabetics].
- Author
-
Alfonso JE and Ariza ID
- Subjects
- Administration, Inhalation, Administration, Oral, Amyloid agonists, Dipeptidyl-Peptidase IV Inhibitors administration & dosage, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Glucagon-Like Peptide 1 analogs & derivatives, Humans, Injections, Subcutaneous, Islet Amyloid Polypeptide, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents adverse effects, Insulin administration & dosage
- Abstract
New medicines for the therapy of the type 1 and type 2 diabetes have been incorporated in the list of traditional drugs: oral agents and injectable insulin. These treatment alternatives have a new mechanism of action that takes advantage of the antidiabetic properties of certain peptides such as amylin and glucagon like peptide-1 (GLP-1), whose levels are wanting or insufficient in diabetes. This is attained through amylin and GLP-1 analogues, although it can also be achieved by inhibiting the enzyme that degrades the latter. Furthermore, a new system to administer insulin in a noninvasive way through inhalation has become available in the market. This paper summarizes the most important and updated findings on the action mechanism, efficacy, adverse effects and indications of these innovative drugs.
- Published
- 2008
- Full Text
- View/download PDF
34. [Raising HDL cholesterol: which is the best strategy?].
- Author
-
Alfonso JE and Ariza ID
- Subjects
- Cardiovascular Diseases metabolism, Cholesterol, LDL metabolism, Clofibric Acid therapeutic use, Exercise, Humans, Meta-Analysis as Topic, Niacin therapeutic use, Piperidines therapeutic use, Pyrazoles therapeutic use, Rimonabant, Risk Factors, Smoking adverse effects, Thiazolidinediones therapeutic use, Cardiovascular Diseases prevention & control, Cholesterol, HDL metabolism, Hypolipidemic Agents therapeutic use
- Abstract
After having reached the objective for the LDL cholesterol levels, it becomes imperative to reach the objective for HDL cholesterol, known for its anti-atherogenic properties, generally confirmed in many epidemiological studies. This review deals, in a clear and concise manner, with the different alternatives available in daily clinical practice to raise the HDL cholesterol levels of patients, to achieve better outcomes in terms of morbidity and mortality in cardiovascular disease.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.